FOXO3 and breast carcinoma: We found that overexpression of FOXO3a inhibited EMT in breast cancer cells, which was evidenced by increased E-cadherin expression in conjunction with a concomitant decreased in the expression of mesenchymal markers vimentin and N-cadherin (Fig. 1E and Supplementary Fig. 2).